[go: up one dir, main page]

HK1231403A1 - 抑制β 表達的核酸 - Google Patents

抑制β 表達的核酸

Info

Publication number
HK1231403A1
HK1231403A1 HK17105191.7A HK17105191A HK1231403A1 HK 1231403 A1 HK1231403 A1 HK 1231403A1 HK 17105191 A HK17105191 A HK 17105191A HK 1231403 A1 HK1231403 A1 HK 1231403A1
Authority
HK
Hong Kong
Prior art keywords
beta2gpi
2gpi
nucleic acid
acid capable
inhibiting expression
Prior art date
Application number
HK17105191.7A
Other languages
English (en)
Inventor
山田陽史
岩井宏徒
桝田和宏
神田美菜子
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of HK1231403A1 publication Critical patent/HK1231403A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK17105191.7A 2014-01-17 2017-05-22 抑制β 表達的核酸 HK1231403A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014007305 2014-01-17
PCT/JP2015/051139 WO2015108162A1 (ja) 2014-01-17 2015-01-16 β２ＧＰＩの発現を抑制する核酸

Publications (1)

Publication Number Publication Date
HK1231403A1 true HK1231403A1 (zh) 2017-12-22

Family

ID=53543045

Family Applications (1)

Application Number Title Priority Date Filing Date
HK17105191.7A HK1231403A1 (zh) 2014-01-17 2017-05-22 抑制β 表達的核酸

Country Status (9)

Country Link
US (3) US20160333346A1 (zh)
EP (1) EP3095867A4 (zh)
JP (1) JPWO2015108162A1 (zh)
KR (1) KR20160108494A (zh)
CN (1) CN105980560A (zh)
AU (1) AU2015206996A1 (zh)
CA (1) CA2937118A1 (zh)
HK (1) HK1231403A1 (zh)
WO (1) WO2015108162A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323892A4 (en) * 2015-07-13 2019-07-17 Kyowa Hakko Kirin Co., Ltd. Antisense oligonucleotide inhibition of 2GPI expression
WO2017010575A1 (ja) * 2015-07-16 2017-01-19 協和発酵キリン株式会社 β２ＧＰＩ遺伝子発現抑制核酸複合体
AU2018232367A1 (en) * 2017-03-09 2019-10-03 Kyowa Kirin Co., Ltd. Nucleic acid capable of inhibiting expression of MASP2

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1056905A (ja) 1996-08-20 1998-03-03 Orion Mach Co Ltd ヘリングボーン型ストールにおける退出ゲートの構造
GB9711919D0 (en) 1997-06-09 1997-08-06 Ciba Geigy Ag Oligonucleotide derivatives
JP2001075164A (ja) 1999-09-06 2001-03-23 Olympus Optical Co Ltd ファインダ内表示装置及びカメラ
DK1309726T4 (en) 2000-03-30 2019-01-28 Whitehead Inst Biomedical Res RNA Sequence-Specific Mediators of RNA Interference
CA2494930C (en) * 2002-08-05 2021-03-09 Atugen Ag Modified forms of interfering rna molecules
JP2005116204A (ja) 2003-10-03 2005-04-28 Daikin Ind Ltd 放電装置および空気浄化装置
US8084599B2 (en) 2004-03-15 2011-12-27 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
AU2005248147A1 (en) * 2004-05-11 2005-12-08 Alphagen Co., Ltd. Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same
WO2006074546A1 (en) * 2005-01-13 2006-07-20 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
EP1842558B1 (en) 2005-01-28 2012-06-13 Kyowa Hakko Kirin Co., Ltd. Composition for inhibiting expression of target gene
WO2008043561A2 (en) 2006-10-11 2008-04-17 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Influenza targets
EP2340309A2 (en) 2008-09-22 2011-07-06 Rxi Pharmaceuticals Corporation Neutral nanotransporters
US9522262B2 (en) * 2010-04-28 2016-12-20 Kimberly-Clark Worldwide, Inc. Medical devices for delivery of siRNA
CA2746981A1 (en) * 2010-08-05 2012-02-05 Replicor Inc. Methods for inhibition of apolipoprotein h
JP5794514B2 (ja) * 2010-11-12 2015-10-14 大日本住友製薬株式会社 腫瘍血管新生阻害剤

Also Published As

Publication number Publication date
US20170247700A1 (en) 2017-08-31
AU2015206996A1 (en) 2016-08-25
CN105980560A (zh) 2016-09-28
CA2937118A1 (en) 2015-07-23
US20160333346A1 (en) 2016-11-17
KR20160108494A (ko) 2016-09-19
WO2015108162A1 (ja) 2015-07-23
JPWO2015108162A1 (ja) 2017-03-23
EP3095867A4 (en) 2018-02-14
US20170247701A1 (en) 2017-08-31
EP3095867A1 (en) 2016-11-23

Similar Documents

Publication Publication Date Title
HRP20190235T1 (hr) Antisensna nukleinska kiselina
IL251584B (en) Dihydropyrrolopyridines ror–gamma inhibitors
IL249619A0 (en) Analysis of nucleic acid sequences
IL246902A0 (en) Dihydropyrrolopyridine ror–gamma inhibitors
ZA201701246B (en) Synthesis of dna
ZA201700880B (en) Polymorphs of selinexor
SG11201610168YA (en) Nucleic acid synthesis techniques
PT3159409T (pt) Ácido nucleico anti-sentido para utilização no tratamento da distrofia muscular de duchenne
GB201408841D0 (en) Nucleic acid processing
SI3845221T1 (sl) Trdne oblike sofosbuvirja
IL246979A0 (en) Crystalline forms of sofosbuvir
SG11201702844VA (en) Photobioreactor
HK1231403A1 (zh) 抑制β 表達的核酸
GB201504459D0 (en) Isolation of DNA
IL249332A0 (en) Crystalline forms of sofosbuvir
HUP1400294A2 (hu) Clopidogrel új alkalmazása
GB201407166D0 (en) Capture of nucleic acids